Evaluation of protease resistant synthetic antimicrobial peptides as a new approach methodology to mitigate bacterial growth in ex vivo human platelet concentrates Authors: Joseph Jackson, Supaksorn Chattagul, Nazli Azodi, Nijah Simmons, William Wimley, Chintamani Atreya Published: 2026 INTRODUCTION Ex vivo platelet concentrates (PCs) are typically stored at room temperature (~22°C), which limits their shelf life to 5–7 days1. These conditions are highly conducive to bacterial growth; even minor, undetectable contamination introduced during collection can rapidly multiply to dangerous levels during storage2–5. While rigorous safety mitigations make transfusion-transmitted bacterial infections (TTBIs) rare, the risk is never zero, and septic transfusion reactions (STRs) remain a significant cause of patient morbidity and mortality6,7. To mitigate this residual risk and protect against emerging pathogens, proactive pre-storage treatments such as chemical and UV-light-based inactivation are routinely used. However, these methods often compromise the quality and efficacy of the final product, primarily due to UV exposure and downstream processing8. Consequently, the transfusion community generally finds that while treated products offer an extra layer of safety, they are less effective than conventional products, often requiring patients to undergo more frequent transfusions9. Therefore, there is a need for pathogen inactivation methods that ensure safety without degrading the natural attributes of the platelets. We recently established a proof of concept for whole blood (WB) safety using bactericidal peptides (D-CONGA and D-CONGA-Q7)10. Developed through “synthetic molecular evolution” (SME), these peptides have D-amino acids and C-terminal amide to ensure stability and resistance to blood proteases. Recently it was reported that a single dose of these peptides at the start of storage successfully achieved complete inactivation of tested bacterial species in whole blood and prevented regrowth for 35 days without causing significant hemolysis or interfering with hemostatic potential10. In this report, we evaluate these potent antimicrobial peptides (AMPs) for their ability to protect ex-vivo stored PCs in plasma from bacterial contamination. We also examined the impact on in vitro quality and functional attributes, including platelet activation, aggregation, and plasma coagulation properties by using three different concentrations of the peptides (4 μM, 8 μM and 20 μM), with the middle concentration being the optimal concentration for bacterial killing as observed in our previous study11. Our results demonstrate that these AMPs can effectively prevent bacterial growth while maintaining product compatibility, suggesting they are a promising new approach methodology (NAM) for safeguarding stored PCs. MATERIALS AND METHODS Human platelet concentrates, and plasma The study involving human subjects was conducted under an approved protocol by the US FDA Research Involving Human Subjects Committee (RIHSC, Exemption Approval #11-036B). Apheresis platelet concentrates (PCs) were sourced from the National Institutes of Health (NIH) Blood Bank, Department of Transfusion Medicine in Bethesda, MD, USA. Apheresis PC samples were stored at 22°C under gentle agitation. Platelet-poor plasma (PPP) was prepared from these PC units by centrifugation at 2,400 × g for 20 minutes using horizontal swing buckets and subsequent careful collection of the supernatant plasma. Bacterial strains and growth conditions Escherichia coli 25922 (Gram-negative bacteria) and Staphylococcus epidermidis 35983 (Gram-positive bacteria) were purchased from American Type Culture Collection (ATCC, USA) and plated on Mueller-Hinton agar (MHB) (ThermoFisher, Waltham, MA, USA)10. Overnight bacterial cultures were grown in cation-adjusted Mueller-Hinton broth (CAMHB) (Sigma Aldrich, St. Louis, MO, USA) until the mid-log phase (OD600=0.3-0.6). Bacterial suspensions were washed and diluted to target inoculum in phosphate-buffered saline (PBS), pH 7.4 (ThermoFisher) to achieve the cell density of 5.0×105 CFU mL−1. The appropriate bacterial target concentrations were determined by a standard dilution method. Antimicrobial peptides (AMP) preparation The peptide preparations were made as previously described10. Briefly, the peptides D-CONGA (rrwarrlafafrramide), and D-CONGA-Q7 (rrwarrqlafafrr-amide) were synthesized at our in-house peptide facility and purified via reverse phase high-performance liquid chromatography. The synthetic peptide stocks were solubilized in 0.025% (v/v) acetic acid (HOAc) and stored at 4°C until processed. On the day of the assay, a working stock concentration of 1 mM was diluted in PBS, pH 7.4 to a final concentration of 256 μM. Stock concentrations of Ampicillin (Amp) and Levofloxacin (LVX), both from Sigma Aldrich were prepared in water, and kept at −20°C until use. Bacterial inactivation kinetics following treatment with AMPs Briefly, all assays were performed in 96-deep well plates. E. coli and S. epidermidis were cultured and prepared at target inoculum10. Each bacteria-spiked platelet samples in the well were treated with either D-CONGA or D-CONGA-Q7, or conventional antibiotics (Amp and LVX, as controls) at concentrations of 8 μM. The positive controls contained only bacteria-spiked samples. After incubation at 37°C, bacterial suspensions were sampled at selected time intervals (0, 1, 2, 3, 4, 5, and 24 h), and bacterial enumeration was determined by using a standard serial dilution protocol. The experiments were performed with three individual replicates. Flow cytometry Flow cytometry was performed to measure P-selectin (CD62P), a marker of platelet activation, after treatment with AMPs. Briefly, apheresis PCs were diluted to 3×108 cells/mL in 100 μL aliquots and subsequently treated with PBS or with 20 μM of either D-CONGA or D-CONGA-Q7 for 3 h at 37°C. After incubation, selected samples were treated with 20 μM TRAP-6, for 15 min at 37°C. All samples were then transferred to ~400 μL of PBS in flow tubes and selectively stained with: 10 μL CD61-FITC and 10 μL CD62P (P-selectin)-APC, both supplied from BD Biosciences (Franklin Lakes, NJ, USA) for 20 min at room temperature in the dark. The samples were then acquired on a CytoFlex flow cytometer (Beckman Coulter, Brea, CA, USA). Samples were initially gated on forward scatter and side-scatter properties, followed by gating for CD61+ platelets, where percentage CD62P is recorded. Data is representative of three independent replicates. Platelet aggregation Apheresis platelet samples were diluted to a target concentration of 2.5×108 cells mL−1 in plasma, subsequently treated with 20 μM of D-CONGA and D-CONGA-Q7, and incubated at 37°C for 3 h. After incubation, the samples were supplemented using a platelet agonist, thrombin receptor activator peptide-6 (20 μM TRAP-6), obtained from AnaSpec, Fremont, CA, USA. Platelet aggregation was measured via light-transmission aggregometry using an AggRAM aggregometer (Helena Laboratories, Beaumont, TX, USA) over 10 min. The baseline aggregation was set to 0% using PPP for each sample prior to testing. The experiments were carried out with at least five replicates from different individual donors. Activated partial thromboplastin time assay of PPP Activated partial thromboplastin time (aPTT) assay was performed to assess the effect of different concentrations of AMPs on clotting time. Briefly, frozen PPP samples were thawed and treated with either 4 μM, 8 μM, or 20 μM concentration of D-CONGA or D-CONGA-Q7 and incubated at 37°C for 3 h. In samples treated with 20 μM AMPs, to withdraw the peptides from the reaction, 1 μg/mL of PolyCAT A™ resin (with a diameter of 30 μM; PolyC, Columbia, MD, USA) was added and incubated for 1hr at room temperature with gentle rotational mixing10. These resin-supplemented samples were then separated from the PPP samples by centrifugation at 50 × g for 2 min. We have previously demonstrated that incubation with this resin allows for the sequestering and removal of the AMPs10. All tested samples were then analyzed for clotting time via aPTT assay using the Synthasil kit (Instrument Technologies, Boise, ID, USA) on the ACLTop 550 coagulation analyzer (Werfen, Bedford, MA, USA). A total of three independent donor PPP samples were used. Statistical analysis Statistical analysis was conducted using GraphPad Prism 10. A one-way ANOVA followed by Tukey’s post hoc tests was used to assess significant differences in platelet aggregation, P-selectin (CD62P) expression, and clotting times between treated and untreated samples, with p<0.001 indicating statistical significance. RESULTS Time-dependent inactivation kinetics of tested bacteria The bactericidal effects of D-CONGA, D-CONGA-Q7, and two internal conventional control antibiotics Amp and LVX, in PCs were evaluated using time-dependent kinetics profiles. The selected bacteria in PCs were treated with both peptides individually at 8 μM as reported in our recent WB10 study and evaluated at various time points over a 24-h period. Since 8 μM was shown to be optimal for effective bacterial killing in the previous study, peptides at a lower concentration (4 μM) or higher concentration (20 μM) relative to 8 μM were not employed in this experiment. The time-dependent inactivation curves demonstrated rapid bactericidal efficacy of both AMPs against E. coli and S. epidermidis (Figure 1). A 5-log10 reduction (99.999%) of E. coli was observed within 2 h of treatment with D-CONGA and ~1 h with D-CONGA-Q7. For S. epidermidis, a 5-log10 reduction was achieved within 3 h of treatment with D-CONGA and 2 h with D-CONGA-Q7 treatment. In comparison, Amp showed no effect against the two tested bacteria, while LVX exhibited a strong bactericidal effect against E. coli (≥5-log10 reduction) and moderate killing activity against S. epidermidis, with a delayed bactericidal effect resulting in a 5-log10 reduction after 24-h of treatment, suggesting potential strain-specific differences in susceptibility. Effect of the AMPs treatment on in vitro functional integrity of PCs We investigated the upper compatibility boundary of AMP treatments on the functional integrity of PCs by assessing platelet activation and aggregation potential following exposure to the peptides. The effect of AMPs on platelet activation was assessed by measuring platelet-surface P-selectin (CD62P), an established indicator of platelet activation, via flow cytometry. The effect of peptide concentrations at 20 μM, which are much higher (2.5×) than the 8 μM used for time-based bactericidal activity, was investigated to test whether this higher concentration negatively affects platelet activation potential. As demonstrated in Figure 2A, exposure to the AMPs did not significantly increase CD62P expression on the platelet surface compared to control samples, suggesting that the treatment is compatible with platelets and does not activate them. PCs treated with positive control, thrombin receptor activated peptide 6 (TRAP-6), resulted in high P-selectin levels. High P-selectin levels were also observed in samples treated with AMPs + TRAP-6 (Figure 2A), suggesting that the peptides do not interfere with the activation capacity of PCs. In similar experiments, platelet aggregation was assessed over time after AMP treatment with or without TRAP-6 activation stimulus. As shown in Figure 2B, PCs treated with AMPs alone did not aggregate in contrast with samples treated with TRAP-6, which positively facilitated platelet aggregation. When PCs were treated with both TRAP-6 + AMPs, platelet aggregation was observed comparably to TRAP-6 only treated samples. Collectively, these data suggest that exposure to high concentrations of AMPs does not induce nor reduce the capacity of platelets to activate and aggregate, suggesting the compatibility of these AMPs with PCs. Effect of the AMPs treatment on PC-derived PPP In this experiment, PPP was treated with three concentrations of both AMPs to study the effects on clotting times: 1) the 8 μM concentration which achieved a 5 log10 bacterial reduction (the ideal concentration), 2) a concentration of 4 μM (0.5× lower than the ideal concentration) and, 3) a concentration of 20 μM (2.5× higher than the ideal concentration). aPTT, a traditional coagulation assay that predominantly assesses the activity of coagulation factors of the intrinsic (contact) and common pathways, was measured using a coagulation analyzer, ACLTop 550 (Werfen). As shown in Figure 3A, PPP treated with 4 μM and 8 μM peptides demonstrated no significant differences between peptide-treated and untreated treated PPP with respect to clotting times, suggesting compatibility of the two peptides at these concentrations for both bacterial inactivation and noninterference with product functions measured in vitro. However, much higher concentrations such as 20 μM do interfere with functions (elevated clotting times) and the elevated levels can be partially restored by capturing the peptides via a cation exchange resin (Figure 3B). DISCUSSION It is imperative that ideal pathogen reduction tools for blood and blood component safety from infectious agents must not only effectively kill the pathogens but also to be compatible with the treated products. This means the treated products meant for transfusion should display in vitro measurable parameters like that of untreated products. In this context, since ex vivo human platelets are typically stored at room temperature (22°C), though rare, platelet associated bacterial contamination with respect to sepsis in transfusion recipients is real, and the risk is not zero6,7. In this context it is worth mentioning that human platelets can also be stored at 1–6°C (cold-stored platelets; CSP). While these cells have different activation potential and physiological characteristics compared to conventional platelets, CSPs have been shown to reduce bacterial contamination during storage10. However, the use of CSPs is reserved for when conventional platelets are not available nor practical, and coupled with potential storage logistical issues, limits its widespread use in clinical settings10. Thus, the development of new and effective pathogen reduction treatments as described in this report is useful for retaining the safety of conventional platelets. Building on our prior demonstration of the bactericidal efficacy of D-CONGA and D-CONGA-Q7 in whole blood (WB)11, this study evaluated the same two synthetic AMPs in apheresis PCs and plasma. We assessed their pathogen-reduction potential against E. coli and S. epidermidis, representing model Gram-negative and Gram-positive species, respectively. The results reported here demonstrated that both peptides achieved complete bacterial inactivation at 8 μM within 1–3 hours of treatment in PCs. To establish a peptide treatment safety margin, we further evaluated a concentration of 20 μM (2.5× the minimum required dose for inactivation) on in vitro platelet quality and functional attributes. Exposure to 20 μM AMPs did not significantly alter platelet activation, as measured by surface P-selectin (CD62P) expression, or aggregation potential following TRAP-6 stimulation. Since the peptide concentrations much higher (20 μM) than required for antimicrobial activity did not affect platelet activation and aggregation potential, we rationalized that lower concentrations (4 μM and 8 μM) would not affect platelet functions either. Hence the two lower concentrations of peptides were not tested for platelet studies. In PPP prepared from PCs, peptide treatment at 4μM (0.5× lower) and 8 μM (ideal) concentrations did not affect clotting times. In contrast, peptide treatment at 20 μM (2.5× higher) significantly prolonged the aPTT results, suggesting interference with the intrinsic or common coagulation pathways. However, this prolonged aPTT was markedly attenuated when AMPs were sequestered from the plasma using a cation exchange resin, consistent with previously reported reversible peptide-binding kinetics11. CONCLUSIONS Overall, these findings suggest that fit-for-purpose synthetic peptides offer a viable path toward enhanced blood safety. Specifically, these two peptides inactivate bacteria while maintaining platelet and plasma functional quality. While the maintenance of platelet quality and the potential for resin-mediated reversal are promising, further validation of this strategy is warranted.